Paolo F Caimi (Paolo Caimi)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 22

Top Topics

Diffuse Large B Cell Lymphoma

Top Venues

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert M Dean, Omer Koc, Kirsten Boughan, Brenda W Cooper, Brad Pohlman, Paolo F Caimi, Mitchell Reed Smith
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leukemia & lymphoma 65 (6) (2024)
Leland L Metheny, Ronald Sobecks, Christina Cho, Pingfu Fu, Seunghee Margevicius, Jiasheng Wang, Lisa Ciarrone, Shelby Kopp, Robin D Convents, Navneet S Majhail, Paolo F Caimi, Folashade Otegbeye, Brenda W Cooper, Molly Gallogly, Ehsan Malek, Benjamin K Tomlinson, Aaron T Gerds, Betty Hamilton, Sergio A Giralt, Miguel-Ángel Perales, Marcos J deLima
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood advances 8 (6) (2024)
Leland Metheny, Ronald M Sobecks, Christina Cho, Pingfu Fu, Seunghee Margevicius, Jiasheng Wang, Lisa Ciarrone, Shelby Kopp, Robin Convents, Navneet S Majhail, Paolo F Caimi, Folashade Otegbeye, Brenda W Cooper, Molly M Gallogly, Ehsan Malek, Benjamin K Tomlinson, Aaron T Gerds, Betty K Hamilton, Sergio A Giralt, Miguel-Ángel Perales, Marcos J deLima
A multicenter study of posttransplant low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood advances (2024)
Leland L Metheny, Ronald Sobecks, Christina Cho, Pingfu Fu, Seunghee Margevicius, Jiasheng Wang, Lisa Ciarrone, Shelby Kopp, Robin D Convents, Navneet S Majhail, Paolo F Caimi, Folashade Otegbeye, Brenda W Cooper, Molly Gallogly, Ehsan Malek, Benjamin K Tomlinson, Aaron T Gerds, Betty Hamilton, Sergio A Giralt, Miguel-Ángel Perales, Marcos J deLima
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood advances 8 (6) (2024)
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert M Dean, Omer Koc, Kirsten Boughan, Brenda W Cooper, Brad Pohlman, Paolo F Caimi, Mitchell Reed Smith
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leukemia & lymphoma 65 (6) (2024)
Paolo F Caimi, Jan Joseph Melenhorst
Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models. Cancer immunology research 12 (4) (2024)
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert M Dean, Omer Koc, Kirsten Boughan, Brenda W Cooper, Brad Pohlman, Paolo F Caimi, Mitchell Reed Smith
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leukemia & lymphoma (2024)
Leland L Metheny, Ronald Sobecks, Christina Cho, Pingfu Fu, Seunghee Margevicius, Jiasheng Wang, Lisa Ciarrone, Shelby Kopp, Robin D Convents, Navneet S Majhail, Paolo F Caimi, Folashade Otegbeye, Brenda W Cooper, Molly Gallogly, Ehsan Malek, Benjamin K Tomlinson, Aaron T Gerds, Betty Hamilton, Sergio A Giralt, Miguel-Ángel Perales, Marcos J deLima
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood advances 8 (6) (2024)
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria Nachar, Jonathan Weiss, Jane Osterson, Krish Patel, Joshua D Brody, Jeremy S Abramson, Matthew A Lunning, Nirav N Shah, Ayed Ayed, Manali Kamdar, Benjamin Parsons, Paolo F Caimi, Ian W Flinn, Alex F Herrera, Jeffrey Sharman, Marshall McKenna, Philippe Armand, Brad S Kahl, Sonali M Smith, Andrew D Zelenetz, L Elizabeth Elizabeth Budde, Martin Hutchings, Tycel Jovelle Phillips, Michael J Dickinson
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood 143 (16) (2024)
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert M Dean, Omer Koc, Kirsten Boughan, Brenda W Cooper, Brad Pohlman, Paolo F Caimi, Mitchell Reed Smith
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leukemia & lymphoma 65 (6) (2024)
David A Qualls, Nicholas Lambert, Paolo F Caimi, Mwanasha H Merrill, Priyanka Pullarkat, Richard C Godby, David A Bond, Graham T Wehmeyer, Jason T Romancik, Behzad Amoozgar, Lori A Leslie, Loretta J Nastoupil, Jennifer L Crombie, Jeremy S Abramson, Arushi Khurana, Grzegorz S Nowakowski, Kami J Maddocks, Sarah C Rutherford, Brad S Kahl, Michelle Okwali, Michael J Buege, Venkatraman E Seshan, Connie Lee Batlevi, Gilles Andre Salles
Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood (2023)
Juan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani, Muthiah Nachiappan, Salman Leslom, Brad S Kahl, Weiyun Z Ai, John Radford, Melham M Solh, Kirit M Ardeshna, Brian T Hess, Matthew A Lunning, Pier Luigi Luigi Zinzani, Anastasios Stathis, Carmello Carlo-Stella, Izidore S Lossos, Paolo F Caimi, Sunwoo Han, Fei Yang, Russ A Kuker, Craig H Moskowitz
PET/CT-biomarkers enable risk stratification of patients with relapsed/refractory diffuse large B-cell lymphoma enrolled in the LOTIS-2 clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Paolo F Caimi, Mehdi Hamadani, Carmello Carlo-Stella, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Danilo Cucchi, Serafino Pantano, Karin E Havenith, Ying Wang, Joseph Boni
In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine. EJHaem 5 (1) (2023)
James N Gerson, Elizabeth Handorf, Diego R Villa, Alina S Gerrie, Parv Chapani, Shaoying Li, L Jeffrey Medeiros, Michael L Wang, Jonathan Cohen, Michael C Churnetski, Brian T Hill, Yazeed Sawalha, Francisco J Hernandez-Ilizaliturri, Shalin K Kothari, Julie M Vose, Martin A Bast, Timothy S Fenske, Swapna Narayana Rao Gari, Kami J Maddocks, David A Bond, Veronika Bachanova, Bhaskar C Kolla, Julio C Chavez, Bijal D Shah, Frederick Lansigan, Timothy F Burns, Alexandra Donovan, Nina D Wagner-Johnston, Marcus Raymond Messmer, Amitkumar Mehta, Jennifer Anderson, Nishitha Reddy, Alexandra Kovach, Daniel J Landsburg, Martha J Glenn, David J Inwards, Kay Ristow, Reem Karmali, Jason Kaplan, Paolo F Caimi, Saurabh A Rajguru, Andrew M Evens, Andreas K Klein, Elvira Umyarova, Bhargavi Pulluri, Jennifer Effie Amengual, Jenniver K Lue, Catherine Diefenbach, Richard I Fisher, Stefan K Barta
Outcomes of Patients with Blastoid and Pleomorphic Variant Mantle Cell Lymphoma. Blood advances (2023)
Paolo F Caimi, Mehdi Hamadani, Carmello Carlo-Stella, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Danilo Cucchi, Serafino Pantano, Karin E Havenith, Ying Wang, Joseph Boni
In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine. EJHaem 5 (1) (2023)
Akiva Diamond, Sabarish Ayyappan, Shufen Cao, Nour Tashtish, Kirsten Boughan, Brenda Cooper, PingFu Fu, Paolo F Caimi
Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B-cell lymphoma and treated with anthracyclines. Hematological oncology 40 (4) (2022)
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara Moyo, Nishitha Reddy, Julia Whitley Sheets, David M Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C Churnetski, Andrew Hsu, Luke D Zurbriggen, Xiao-Wei Cherie Tan, Kathryn G Lindsey, Joseph Maakaron, Paolo F Caimi, Pallawi Torka, Celeste Bello, Sabarish Ayyappan, Timothy S Oh, Reem Karmali, Seo-Hyun Kim, Anna Kress, Shalin Kothari, Yazeed Sawalha, Beth Christian, Kevin A David, Irl Brian Greenwell, Murali Janakiram, Vaishalee P Kenkre, Adam J Olszewski, Jonathon B Cohen, Neil Palmisiano, Elvira R Umyarova, Ryan A Wilcox, Farrukh T Awan, Juan Pablo Alderuccio, Stefan K Barta, Natalie Sophia Grover, Nilanjan Ghosh, Nancy L Bartlett, Alex F Herrera, Geoffrey Shouse
Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood advances (2022)
Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S Fenske, Pier Luigi Luigi Zinzani, Manish R Patel, Nilanjan Ghosh, Bruce D Cheson, Enrico Derenzini, Danielle M Brander, James A Reeves, Wanda Knopińska-Posłuszny, John N Allan, Tycel Phillips, Paolo F Caimi, Ewa Lech-Maranda, John M Burke, Richy Agajanian, Ruth Pettengell, Lori A Leslie, Chan Yoon Y Cheah, Gustavo Fonseca, James Essell, Julio C Chavez, John M Pagel, Jeff P Sharman, Yanzhi Hsu, Hari P Miskin, Peter Sportelli, Michael S Weiss, Ian W Flinn
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies. Blood advances 5 (23) (2022)
Juan Pablo Alderuccio, Weiyun Z Ai, John Radford, Melhem Solh, Kirit M Ardeshna, Matthew A Lunning, Brian T Hess, Pier L Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F Caimi
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood advances 6 (16) (2022)
Nathan H Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A Reeves, Wanda Knopińska-Posłuszny, Chan Yoon Y Cheah, Tycel Jovelle Phillips, Ewa Lech-Maranda, Bruce D Cheson, Paolo F Caimi, Sebastian Grosicki, Lori A Leslie, Julio C Chavez, Gustavo Fonseca, Sunil Babu, Daniel James Hodson, Spencer H Shao, John M Burke, Jeff P Sharman, Jennie Y Law, John M Pagel, Hari P Miskin, Peter Sportelli, Owen A O'Connor, Michael S Weiss, Pier Luigi Luigi Zinzani
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (15) (2021)
Krishna Goparaju, Paolo F Caimi
Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma. Expert opinion on biological therapy 21 (11) (2021)
Gouri Dharmavaram, Shufen Cao, Suchitra Sundaram, Sabarish Ayyappan, Kirsten Boughan, Molly Gallogly, Ehsan Malek, Leland Metheny, Benjamin K Tomlinson, Folashade Otegbeye, Hillard M Lazarus, Brenda Cooper, Pingfu Fu, Marcos de Lima, Paolo F Caimi
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction models. American journal of hematology 95 (8) (2020)